Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B

Perrillo, Robert P.; Regenstein, Fredric; Bodicky, Carol J.; Campbell, Carolyn; Sanders, Gary E.; Sunwoo, Young C.

doi:10.1016/0016-5085(85)90151-9

Cited by 90 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12] observed a high rate of clearance of HBV replication in patients with CAH type B, while the results of studies on corticosteroid withdrawal conducted by other authors are far less encouraging, since the elimination of HBcAg was infrequent and in some cases prolonged deterioration of liver disease was observed [4,6,13]. The results of several studies suggest that a combination therapy, in which corticosteroid is followed by anti viral drugs, is superior to corticosteroid withdrawal alone [14,15].…”

Section: Discussionmentioning

confidence: 91%

Short-Term Corticosteroid Therapy for Chronic Active Hepatitis B

Laskus¹,

Cianciara²,

Loch³

et al. 1990

Digestion

View full text Add to dashboard Cite

Seventeen patients with chronic active type B hepatitis were treated with prednisone for 4 weeks. All were initially hepatitis B e antigen (HB_eAg)-positive and 14 were DNA-polymerase-positive as well. In the follow-up period of 1 year, 10 patients became persistently negative for DNA polymerase and 11 cleared HB_eAg from serum, while among 17 matched untreated controls only one lost DNA polymerase and HB_eAg. However, 1 patient who was initially DNA-polymerase-negative and who lost HB_eAg after treatment reactivated to HB_eAg after 4 months and DNA polymerase appeared in his serum. He suffered prolonged exacerbation of liver disease after treatment and died of liver failure. Short-term corticosteroid therapy may be of value in patients with chronic active type B hepatitis, however, in some cases such treatment may be disastrous.

show abstract

Section: Discussionmentioning

confidence: 91%

Short-Term Corticosteroid Therapy for Chronic Active Hepatitis B

Laskus¹,

Cianciara²,

Loch³

et al. 1990

Digestion

View full text Add to dashboard Cite

show abstract

“…Hierbei wurden schon frühzeitig zentralnervöse Nebenwirkungen vermutet (3, 9, 11,14,16,20), die sich später bei Patienten mit Hepatitis, die einer entsprechenden Behandlung unterzogen wurden, bestätigten (1, 15). Seit einigen Jahren werden auch periphere Nervenschäden bei Vidarabin-Therapie mitgeteilt (4-7,10, 12,13,15,18 …”

Section: Polyneuropathie Bei Behandlung Der Chronischen Hepatitis B Munclassified

“…In der Literatur trat das »severe pain Syndrome« (15) ebenfalls teilweise noch während der Therapie mit Vidarabin (4, 6, 10, 12,13,16,18) …”

Section: Diskussionunclassified

Polyneuropathie bei Behandlung der chronischen Hepatitis B mit Vidarabin

Krause

Raedsch²,

Brosi³

et al. 2008

Dtsch med Wochenschr

View full text Add to dashboard Cite

“…Trials confirmed that an inhibitory effect was seen on HBV replication with a decrease in the HBV DNA levels. Clinical trials reported varying rates of sustained response (Perrillo et al, 1985;Trepo et al, 1984). It became apparent that longer term dosing was associated, as reported with several other nucleoside analogues, with significant neurotoxicity and the development of peripheral neuropathy (Garcia et al, 1987).…”

Section: Nucleoside Analoguesmentioning

confidence: 99%

Treatment of Chronic Viral Hepatitis

Main

McCarron

1998

Antivir Chem Chemother

View full text Add to dashboard Cite

Interferon-α therapy has proved effective for up to 40% of patients with adult-acquired chronic hepatitis B virus (HBV) infection and for 20-25% of those with chronic hepatitis C virus (HCV) infection. Nucleoside analogues, such as lamivudine and famciclovir, are showing promise as antiviral agents for chronic HBV and the combination of interferon-α and ribavirin is proving to be successful therapy for 40-50% of patients with chronic HCV. In this article we review current therapy and discuss future strategies of the therapy of chronic viral hepatitis.

show abstract

Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B

Cited by 90 publications

References 14 publications

Short-Term Corticosteroid Therapy for Chronic Active Hepatitis B

Short-Term Corticosteroid Therapy for Chronic Active Hepatitis B

Polyneuropathie bei Behandlung der chronischen Hepatitis B mit Vidarabin

Treatment of Chronic Viral Hepatitis

Contact Info

Product

Resources

About